PMD Device Solutions AB Stock

Equities

PMDS

SE0021513645

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Stockholm 08:36:24 2024-06-27 EDT 5-day change 1st Jan Change
5.35 SEK -13.71% Intraday chart for PMD Device Solutions AB +26.78% -45.08%

Financials

Sales 2024 * 51M 4.82M 6.59M Sales 2025 * 77M 7.27M 9.95M Capitalization 129M 12.21M 16.71M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 3.17 x
Net Debt 2024 * 32.5M 3.07M 4.2M Net cash position 2025 * 84M 7.93M 10.86M EV / Sales 2025 * 0.59 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 26
Yield 2024 *
-
Yield 2025 *
-
Free-Float 26.73%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on PMD Device Solutions AB

1 day-13.71%
1 week+26.78%
Current month-20.15%
1 month-35.93%
3 months-43.98%
More quotes
1 week
4.16
Extreme 4.16
7.60
1 month
4.08
Extreme 4.08
8.45
Current year
4.08
Extreme 4.08
112.64
1 year
4.08
Extreme 4.08
112.64
3 years
4.08
Extreme 4.08
112.64
5 years
4.08
Extreme 4.08
112.64
10 years
4.08
Extreme 4.08
112.64
More quotes
Date Price Change Volume
24-06-27 5.35 -13.71% 29 714
24-06-26 6.2 +45.54% 168,359
24-06-25 4.26 -0.47% 2,825
24-06-24 4.28 +1.42% 5,141
24-06-20 4.22 -0.94% 7,007

Delayed Quote Nasdaq Stockholm, June 27, 2024 at 08:36 am

More quotes
PMD Device Solutions AB is a Sweden-based biopharmaceutical company. The Company deals with research, development and production of medical technical products and equipment and related activities. It specializes in the development of therapeutic peptides for the bioactive wound care market. The Company possesses two therapeutic peptides, PXL01 and LL-37, in late stage clinical phase. The peptides are derived from human sequences that are part of innate immune system, having multiple biological functions and properties. PXL01 aims to prevent post-surgical adhesions and scars and is for clinical phase III-studies on patients performing tendon repair surgery in the hand. LL-37 aims to heal chronic wounds and is in a clinical phase IIb study on patients with venous leg ulcers and in a clinical phase IIa study on patients with diabetic foot ulcers. PMD Device Solutions AB develops and sells medical products for respiratory monitoring.
Calendar
More about the company

Chiffre d''affaires - Rate of surprise